Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
2.200
-0.050 (-2.22%)
At close: Jan 22, 2026, 4:00 PM EST
2.240
+0.040 (1.82%)
After-hours: Jan 22, 2026, 4:10 PM EST
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $25.00K in the quarter ending September 30, 2025, a decrease of -87.18%. This brings the company's revenue in the last twelve months to $600.00K, down -59.21% year-over-year. In the year 2024, Lyra Therapeutics had annual revenue of $1.53M, down -1.54%.
Revenue (ttm)
$600.00K
Revenue Growth
-59.21%
P/S Ratio
5.27
Revenue / Employee
$20,000
Employees
30
Market Cap
3.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.53M | -24.00K | -1.54% |
| Dec 31, 2023 | 1.56M | 195.00K | 14.31% |
| Dec 31, 2022 | 1.36M | 1.08M | 378.25% |
| Dec 31, 2021 | 285.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLYRA News
- 10 days ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 2 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 7 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 8 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 8 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire